ArticleEndocrine, metabolic & immune disorders drug targets2026
Efficacy of Once-weekly Somatrogon in Children with Growth Hormone Deficiency After Switching from Daily Therapy
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-acting Growth Hormone (LAGH) analogs represent a promising alternative to daily Growth Hormone (GH) therapy, aiming to improve adherence without compromising efficacy. Among them, somatrogon is the only LAGH currently available in Italy for pediatric use.
objectiveThe objective of this study is to evaluate growth outcomes and IGF-1 variability along with adherence in pediatric patients with Growth Hormone Deficiency (GHD) after switching from daily GH to weekly somatrogon.
methodsThis retrospective, monocentric study involved 23 children and adolescents affected by GHD and in treatment with somatrogon for at least 12 months, after switching from daily therapy. We analyzed changes in growth velocity, serum IGF-1 and height velocity compared to target age-based references before and after the switch. To account for the age-related variability in our cohort, IGF-1 levels were then expressed as Standard Deviation Score (IGF-1 SDS), to quantify how much an individual value deviates from the age and sex-matched population mean. A questionnaire was administered to evaluate adherence and patients’ preferences.
resultsMean height velocity was slightly higher after the therapeutic switch (7.91 ± 1.7 cm/year vs. 7.12 ± 1.3 cm/year, p = 0.04), but no significant differences were observed when growth velocity was normalized to age-based targets or when comparing IGF-1 and IGF-1 SDS levels. Patients preferred the weekly therapy, even if missing doses and a few side effects were still reported. DISCUSSION: Our findings suggest that somatrogon treatment is as effective as daily GH treatment in terms of growth velocity and IGF-1 levels in a pediatric population with growth hormone deficiency. Weekly therapy also seemed to be more manageable for the patients and their families.
conclusionWeekly somatrogon maintains growth-promoting effects comparable to daily GH therapy in pediatric patients with GHD. Patients’ adherence and satisfaction contribute to making this therapy a valid alternative to daily treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.